Research Summary

My main research interests are in understanding how diet, exercise, other lifestyle factors, and genetics contribute to cancer progression and death. Our program aims to identify modifiable lifestyle risk factors for cancer progression, use this information to better understand cancer biology, and inform public health guidelines. I have worked in this area, with a specific focus on prostate cancer, for ~20 years. Our work is highly collaborative - our clinical and translational studies work to identify risk-reduction strategies for men with or at high risk for prostate cancer, evaluate novel molecular markers of prostate cancer aggressiveness that may improve screening, diagnosis, or prognosis of clinically relevant disease, and improve cancer survivorship for the millions of men living with prostate cancer worldwide.

I lead the Diet and Lifestyle Study within the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE); am PI of a randomized clinical trial examining an exercise intervention among men pursuing active surveillance for prostate cancer; co-PI on a large Dept. of Defense Translational Impact Award focused on improving risk stratification and decision support for men considering active surveillance for low risk prostate cancer; serve on the steering committee for a global clinical trial of exercise among men with metastatic prostate cancer; and am co-investigator on a trial examining a 2 year remotely monitored blended diet and exercise intervention for men undergoing surgery for prostate cancer. I also collaborate with team members on lifestyle interventions and observational research in bladder and colorectal cancer survivors.

Research Funding

  • April 14, 2014 - February 28, 2021 - Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer Prognosis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA181802
  • September 1, 2006 - August 31, 2011 - Prostate Microenvironmental &Prostate Cancer Progression , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA106947

Education

Harvard College, Cambridge, MA , B.A., 1994, Applied Math in Biology
Harvard School of Public Health, Boston, MA, ScD, 11/98, Epidemiology (Cancer)
Harvard School of Public Health, Boston, MA, 11/98-11/00, Postdoctoral Fellow-Epidemiology

Honors & Awards

  • 1994-96
    Fulbright Scholar, Uppsala University, Sweden, Dept. of Medical Epidemiology
  • 1996 & 1997
    Pforzheimer Public Service Fellowship, Harvard University
  • 1998
    Society for Epidemiologic Research Abraham Lilienfeld Student Prize
  • 1998
    Association for the Cure of Cancer of the Prostate ("CaPCURE") - Young Investigator Award
  • 2000
    AACR-AFLAC Young Investigator Scholars in Cancer Research Award
  • 2001
    REAC Intramural award, UCSF
  • 2002
    AACR-California Department of Health Services Early Career Development Award in Gender-Related Cancer Research (prostate)
  • 2003
    Prostate Cancer Foundation ("CaPCURE") - Competitive Award (6/03 & 12/03)
  • UCSF Equal Opportunity Faculty Development Award
  • 2009
    Awarded Steven & Christine Burd-Safeway Distinguished Professorship, Urology, UCSF

Selected Publications

  1. Wang L, Langlais C, Kenfield SA, Van Loon K, Laffan A, Atreya CE, Chan JM, Zhang L, Allen IE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP, Van Blarigan EL. Quality of life among colorectal cancer survivors participating in a pilot randomized controlled trial of a web-based dietary intervention with text messages. Support Care Cancer. 2023 Feb 10; 31(3):155.  View on PubMed
  2. Van Blarigan EL, Chan JM, Sanchez A, Zhang L, Winters-Stone K, Liu V, Macaire G, Panchal N, Graff RE, Tenggara I, Luke A, Simko JP, Cooperberg MR, Carroll PR, Kenfield SA. Protocol for a 4-arm randomized controlled trial testing remotely delivered exercise-only, diet-only, and exercise + diet interventions among men with prostate cancer treated with radical prostatectomy (Prostate 8-II). Contemp Clin Trials. 2023 Jan 05; 125:107079.  View on PubMed
  3. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2022 Dec 15.  View on PubMed
  4. Kenfield SA, Philip EJ, Phillips SM, Meyerhardt JA, Chan JM, Atreya CE, Kim MO, Harris Q, Steiding P, Macaire G, McCullough ML, Piawah S, Johnson WY, Kurttila FA, Lewis WL, Pesmen C, Watson Y, Van Blarigan EL. Optimizing intervention tools to improve nutrition and physical activity for colorectal cancer survivors (Tools To Be Fit): Study protocol of a randomized factorial experiment. Contemp Clin Trials. 2022 12; 123:107009.  View on PubMed
  5. Greenberg AL, Tolstykh IV, Van Loon K, Laffan A, Stanfield D, Steiding P, Kenfield SA, Chan JM, Atreya CE, Piawah S, Kidder W, Venook AP, Van Blarigan EL, Varma MG. Association between adherence to the American Cancer Society Nutrition and Physical Activity Guidelines and stool frequency among colon cancer survivors: a cohort study. J Cancer Surviv. 2022 Nov 05.  View on PubMed
  6. Smith LH, Garc?a-Alb?niz X, Chan JM, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR, Hern?n MA. Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula. Eur J Epidemiol. 2022 Dec; 37(12):1205-1213.  View on PubMed
  7. Langlais CS, Graff RE, Van Blarigan EL, Kenfield SA, Neuhaus J, Tabung FK, Cowan JE, Broering JM, Carroll P, Chan JM. Postdiagnostic Inflammatory, Hyperinsulinemic, and Insulin-Resistant Diets and Lifestyles and the Risk of Prostate Cancer Progression and Mortality. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1760-1768.  View on PubMed
  8. Graff RE, Langlais CS, Van Blarigan EL, Pernar CH, Stampfer MJ, Giovannucci EL, Mucci LA, Chan JM, Kenfield SA. Post-diagnostic health behaviour scores in relation to fatal prostate cancer. Br J Cancer. 2022 11; 127(9):1670-1679.  View on PubMed
  9. Wang L, Langlais CS, Kenfield SA, Chan JM, Graff RE, Allen IE, Atreya CE, Van Blarigan EL. mHealth Interventions to Promote a Healthy Diet and Physical Activity among Cancer Survivors: A Systematic Review of Randomized Controlled Trials. Cancers (Basel). 2022 Aug 06; 14(15).  View on PubMed
  10. Loeb S, Fu BC, Bauer SR, Pernar CH, Chan JM, Van Blarigan EL, Giovannucci EL, Kenfield SA, Mucci LA. Association of plant-based diet index with prostate cancer risk. Am J Clin Nutr. 2022 03 04; 115(3):662-670.  View on PubMed
  11. Kenfield SA, Chan JM. More evidence that physical activity is beneficial for prostate cancer. Prostate Cancer Prostatic Dis. 2022 09; 25(3):383-384.  View on PubMed
  12. Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya C, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP, Van Blarigan EL. Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages. Support Care Cancer. 2022 May; 30(5):4557-4564.  View on PubMed
  13. Van Blarigan EL, Dhruva A, Atreya CE, Kenfield SA, Chan JM, Milloy A, Kim I, Steiding P, Laffan A, Zhang L, Piawah S, Fukuoka Y, Miaskowski C, Hecht FM, Kim MO, Venook AP, Van Loon K. Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II). JMIR Cancer. 2022 Jan 11; 8(1):e31576.  View on PubMed
  14. Chirikova E, McConnell RJ, O'Kane P, Yauseyenka V, Little MP, Minenko V, Drozdovitch V, Veyalkin I, Hatch M, Chan JM, Huang CY, Mabuchi K, Cahoon EK, Rozhko A, Zablotska LB. Association between exposure to radioactive iodine after the Chernobyl accident and thyroid volume in Belarus 10-15 years later. Environ Health. 2022 01 07; 21(1):5.  View on PubMed
  15. Langlais CS, Chen YH, Van Blarigan EL, Kenfield SA, Kessler ER, Daniel K, Ramsdill JW, Beer TM, Graff RE, Paich K, Chan JM, Winters-Stone KM. Quality of Life of Prostate Cancer Survivors Participating in a Remotely Delivered Web-Based Behavioral Intervention Pilot Randomized Trial. Integr Cancer Ther. 2022 Jan-Dec; 21:15347354211063500.  View on PubMed
  16. Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13; 3(1).  View on PubMed
  17. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 11; 10(22):8058-8070.  View on PubMed
  18. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ, Collaborators. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021 11; 206(5):1147-1156.  View on PubMed
  19. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Reply by Authors. J Urol. 2021 11; 206(5):1156.  View on PubMed
  20. Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urol Oncol. 2021 10; 39(10):730.e9-730.e15.  View on PubMed

Go to UCSF Profiles, powered by CTSI